<DOC>
	<DOCNO>NCT00651703</DOCNO>
	<brief_summary>The purpose study evaluate specific cellular immune response melanoma patient vaccinate Melan-A VLP vaccine alone combination different adjuvant .</brief_summary>
	<brief_title>Safety Immunogenicity CYT004-MelQbG10 Vaccine With Without Adjuvant Advanced Stage Melanoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Histological confirm Stage III IV malignant melanoma HLAA*0201 haplotype Expected survival least 9 month Willing able comply trial requirement ( e.g . diary , CTs ) Given write informed consent Females nonreproductive agree consistently practice effective accept method contraception Any contraindication study related test assessment Current plan use contraindicate concomitant medication Presence history relevant cardiovascular , renal , pulmonary , endocrine , autoimmune , neurological psychiatric disease Infection HIV , HBV HCV Pregnancy lactation female plan become pregnant study Abuse alcohol drug Use investigational drug within 30 day enrolment Previous participation clinical trial Qbbased Cytos vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>